Figure 5.
Figure 5. Altered tyrosine phosphorylation in response to GPVI and CLEC-2 agonists in G6bhu/hu platelets. Representative blots (n = 3) of lysates prepared from washed platelets (4 × 108/mL) activated with indicated concentrations of (Ai) CRP (90 seconds, 10 μM lotrafiban, 10 μM indomethacin, and 2 U/mL apyrase) or (Bi) CLEC-2 Ab (300 seconds, 10 μM lotrafiban) and probed with the indicated antibodies. (Aii,Bii) Src family kinase (SFK) phosphotyrosine 418 (pTyr418) and (Aiii,Biii) Syk pTyr519/20 were quantified using ImageJ and normalized to total tubulin and Syk reblots, respectively. WT, blue; G6bhu/hu, red.

Altered tyrosine phosphorylation in response to GPVI and CLEC-2 agonists in G6bhu/huplatelets. Representative blots (n = 3) of lysates prepared from washed platelets (4 × 108/mL) activated with indicated concentrations of (Ai) CRP (90 seconds, 10 μM lotrafiban, 10 μM indomethacin, and 2 U/mL apyrase) or (Bi) CLEC-2 Ab (300 seconds, 10 μM lotrafiban) and probed with the indicated antibodies. (Aii,Bii) Src family kinase (SFK) phosphotyrosine 418 (pTyr418) and (Aiii,Biii) Syk pTyr519/20 were quantified using ImageJ and normalized to total tubulin and Syk reblots, respectively. WT, blue; G6bhu/hu, red.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal